Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as an entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Planners:
Vanessa Carranza, PharmD – has no relevant financial relationships to disclose in relation to the content of this activity.
Robert L. Ferris, MD, PhD – has disclosed that he is a consultant for Amgen, AstraZeneca/MedImmune, Benitec, Bristol-Myers Squibb, EMD Serono, Lilly, Merck, and Pfizer. He also receives grant/research support from AstraZeneca/MedImmune, Bristol-Myers Squibb, Merck, and Venti Rx.
Naiyer A. Rizvi, MD – has disclosed that he is a consultant for AstraZeneca, Merck, Novartis, and Roche. He is also a major stock shareholder in Gritstone Oncology.

Authors/Presenters:
Sanjiv S. Agarwala, MD – has no relevant financial relationships to disclose in relation to the content of this activity.
Michael B. Atkins, MD – has disclosed that he is a consultant for Bristol-Myers Squibb, Merck, Novartis, Pfizer, and Roche.
Arjun V. Balar, MD - has disclosed that he is a consultant for AstraZeneca/MedImmune, Genetech, Roche, Merck, and Pfizer. He also receives grant/research support from Genetech, Roche, and Merck.
Robert L. Ferris, MD, PhD – has disclosed that he is a consultant for Amgen, AstraZeneca/MedImmune, Benitec, Bristol-Myers Squibb, EMD Serono, Lilly, Merck, and Pfizer. He also receives grant/research support from AstraZeneca/MedImmune, Bristol-Myers Squibb, Merck, and Venti Rx.
Brent Hanks, MD, PhD – has disclosed that he receives grant/research support from AstraZeneca, Merck, and OncoMed. He also is a major stock shareholder for Bellicum Pharmaceuticals.
Jason J. Luke, MD, FACP – has disclosed that he is a consultant for Actymthera, Amgen, Array, AstraZeneca, BeneVir, Bristol-Myers Squibb, Castle, CheckMate, EMD Serono, Gilead, Novartis, Merck, and 7 Hills. His institution receives grant/research support from AbbVie, Boston Biomedical, Bristol-Myers Squibb, Celldex, Corvus, Delcath, Five Prime, Genentech, Immunocore, Incyte, Intensity, MedImmune Macrogenics, Novartis, Pharmacyclics, Merck, and Tesaro.
Jose Lutzky, MD – has disclosed that he is a member of the speakers’ bureaus for Bristol-Myers Squibb and Novartis.
Isabella C. Glitza Oliva, MD, PhD - has no relevant financial relationships to disclose in relation to the content of this activity.
Sandip Patel, MD – has disclosed that he is a consultant for Bristol-Myers Squibb and Novartis; receives research/grant support from Bristol-Myers Squibb, Lilly, Fate, Incyte, MedImmune, Merck, Pfizer, Roche/Genentech, Xcovery; and a member of the speakers’ bureaus for Boehringer Ingelheim and Merck.
Naiyer A. Rizvi, MD – has disclosed that he is a consultant for AstraZeneca, Merck, Novartis, and Roche. He is also a major stock shareholder in Gritstone Oncology.

Reviewers:
Marianne Davies DNP, ACNP, AOCNP – has disclosed that she is a member of the speakers’ bureaus for AstraZeneca, Bristol-Myers Squibb, Genentech, and Merck.
Adebayo Ogunniyi, PharmD, MPA, BCOP – has no relevant financial relationships to disclose in relation to the content of this activity.